Naturally occurring isothiocyanates exert anticancer effects by inhibiting deubiquitinating enzymes

Cancer Research

Volumn 75, Issue 23, 2015, Pages 5130-5142

  Lawson, Ann P ^a   Long, Marcus J C ^a   Coffey, Rory T ^a   Qian, Yu ^b   Weerapana, Eranthie ^b   El Oualid, Farid ^c   Hedstrom, Lizbeth ^a  

^a BRANDEIS UNIVERSITY   (United States)

^b BOSTON COLLEGE   (United States)

^c UbiQ Bio BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BENZYL ISOTHIOCYANATE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; DEUBIQUITINASE; ENZYME INHIBITOR; HYBRID PROTEIN; ISOTHIOCYANIC ACID DERIVATIVE; PHENETHYL ISOTHIOCYANATE; PROTEIN MCL 1; SULFORAPHANE; UNCLASSIFIED DRUG; WP 1130; PROTEINASE; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; UBIQUITIN THIOLESTERASE; UCHL5 PROTEIN, HUMAN; UCHL5 PROTEIN, MOUSE; USP9X PROTEIN, HUMAN; USP9X PROTEIN, MOUSE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CARCINOGENESIS; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA REPAIR; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; GENE SILENCING; HUMAN; HUMAN CELL; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RNA INTERFERENCE; UBIQUITINATION; VEGETABLE; 3T3 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHLOROCEBUS AETHIOPS; COS CELL LINE; DRUG EFFECTS; EXPERIMENTAL MELANOMA; HELA CELL LINE; K-562 CELL LINE; MCF-7 CELL LINE; METABOLISM; MOUSE;

ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; ENDOPEPTIDASES; HELA CELLS; HUMANS; ISOTHIOCYANATES; K562 CELLS; MCF-7 CELLS; MELANOMA, EXPERIMENTAL; MICE; NIH 3T3 CELLS; UBIQUITIN; UBIQUITIN THIOLESTERASE; UBIQUITIN-PROTEIN LIGASE COMPLEXES; UBIQUITINATION;

EID: 84955493429     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-1544     Document Type: Article

References (50)

1. Mi L, Di Pasqua AJ, Chung FL. Proteins as binding targets of isothiocyanates in cancer prevention. Carcinogenesis 2011;32:1405-13.
2. Singh SV, Singh K. Cancer chemoprevention with dietary isothiocyanates mature for clinical translational research. Carcinogenesis 2012;33: 1833-42.
3. Gupta P, Kim B, Kim SH, Srivastava SK. Molecular targets ofisothiocyanates in cancer: recent advances. Mol Nutr Food Res 2014;58:1685-707.
4. Cramer JM, Teran-Garcia M, Jeffery EH. Enhancing sulforaphane absorption and excretion in healthy men through the combined consumption of fresh broccoli sprouts and a glucoraphanin-rich powder. Br J Nutr 2012; 107:1333-8.
5. Zhang Y, Tang L, Gonzalez V. Selected isothiocyanates rapidly induce growth inhibition of cancer cells. Mol Cancer Ther 2003;2:1045-52.
6. Popovic D, Vucic D, Dikic I. Ubiquitination in disease pathogenesis and treatment. Nat Med 2014;20:1242-53.
7. Gao N, Budhraja A, Cheng S, Liu EH, Chen J, Yang Z, et al. Phenethyl isothiocyanate exhibits antileukemic activity in vitro and in vivo by inactivation of Akt and activation of JNK pathways. Cell Death Dis 2011;2:e140.
8. Zhou T, Li G, Cao B, Liu L, Cheng Q, Kong H, et al. Downregulation of Mcl-1 through inhibition of translation contributes to benzyl isothiocyanate-induced cell cycle arrest and apoptosis in human leukemia cells. Cell Death Dis 2013;4:e515.
9. Trachootham D, Zhang H, Zhang W, Feng L, Du M, Zhou Y, et al. Effective elimination of fludarabine-resistant CLL cells by PEITC through a redoxmediated mechanism. Blood 2008;112:1912-22.
10. Zhang H, Trachootham D, Lu W, Carew J, Giles FJ, Keating MJ, et al. Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia 2008;22:1191-9.
11. Hu Y, Lu W, Chen G, Zhang H, Jia Y, Wei Y, et al. Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound beta-phenylethyl isothiocyanate. Blood 2010;116: 2732-41.
12. Zhu C, Hu W, Wu H, Hu X. No evident dose-response relationship between cellular ROS level and its cytotoxicity - a paradoxical issue in ROS-based cancer therapy. Sci Rep 2014;4:5029.
13. Tang CS, Tang WJ. Inhibition of papain by isothiocyanates. Biochim Biophys Acta 1976;452:510-20.
14. Nicholson B, Kumar S, Agarwal S, Eddins M, Marblestone JG, Wu J, et al. Discovery of therapeutic deubiquitylase effector molecules: current perspectives. J Biomol Screen 2014;19:989-99.
15. Luise C, Capra M, Donzelli M, Mazzarol G, Jodice MG, Nuciforo P, et al. An atlas of altered expression of deubiquitinating enzymes in human cancer. PLoS One 2011;6:e15891.
16. Borodovsky A, Ovaa H, Kolli N, Gan-Erdene T, Wilkinson KD, Ploegh HL, et al. Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family. Chem Biol 2002;9:1149-59.
17. Kisselev AF, Akopian TN, Castillo V, Goldberg AL. Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown. Mol Cell 1999;4:395-402.
18. Qian Y, Martell J, Pace NJ, Ballard TE, Johnson DS, Weerapana E. An isotopically tagged azobenzene-based cleavable linker for quantitative proteomics. Chembiochem 2013;14:1410-4.
19. Weerapana E, Speers AE, Cravatt BF. Tandem orthogonal proteolysis-activity-based protein profiling (TOP-ABPP) - a general method for mapping sites of probe modification in proteomes. Nat Protoc 2007;2: 1414-25.
20. Zhang X, Ren R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 1998;92:3829-40.
21. Dantuma NP, Lindsten K, Glas R, Jellne M, Masucci MG. Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nat Biotechnol 2000;18:538-43.
22. Liu G, Rogers J, Murphy CT, Rongo C. EGF signalling activates the ubiquitin proteasome system to modulate C. elegans lifespan. EMBO J 2011;30: 2990-3003.
23. Um JW, Im E, Lee HJ, Min B, Yoo L, Yoo J, et al. Parkin directly modulates 26S proteasome activity. J Neurosci 2010;30:11805-14.
24. Mi L, Gan N, Chung FL. Isothiocyanates inhibit proteasome activity and proliferation of multiple myeloma cells. Carcinogenesis 2011;32: 216-23.
25. Kramer HB, Nicholson B, Kessler BM, Altun M. Detection of ubiquitin-proteasome enzymatic activities in cells: application of activity-based probes to inhibitor development. Biochim Biophys Acta 2012;1823: 2029-37.
26. de Jong A, Merkx R, Berlin I, Rodenko B, Wijdeven RH, ElAtmioui D, et al. Ubiquitin-based probes prepared bytotal synthesis to profile the activity of deubiquitinating enzymes. Chembiochem 2012;13:2251-8.
27. Ekkebus R, van Kasteren SI, Kulathu Y, Scholten A, Berlin I, Geurink PP, et al. On terminal alkynes that can react with active-site cysteine nucleophiles in proteases. J Am Chem Soc 2013;135:2867-70.
28. Sommer S, Weikart ND, Linne U, Mootz HD. Covalent inhibition of SUMO and ubiquitin-specific cysteine proteases by an in situ thiol-alkyne addition. Bioorg Med Chem 2013;21:2511-7.
29. Kapuria V, Peterson LF, Fang D, Bornmann WG, Talpaz M, Donato NJ. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res 2010;70:9265-76.
30. Chen YJ, Ma YS, Fang Y, Wang Y, Fu D, Shen XZ. Power and promise of ubiquitin carboxyl-terminal hydrolase 37 as a target of cancer therapy. Asian Pac J Cancer Prev 2013;14:2173-9.
31. Peng J, Hu Q, Liu W, He X, Cui L, Chen X, et al. USP9X expression correlates with tumor progression and poor prognosis in esophageal squamous cell carcinoma. Diagn Pathol 2013;8:177.
32. Peddaboina C, Jupiter D, Fletcher S, Yap JL, Rai A, Tobin RP, et al. The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition. BMC Cancer 2012;12:541.
33. Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM, et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 2010;463:103-7.
34. Sun H, Kapuria V, Peterson LF, Fang D, Bornmann WG, Bartholomeusz G, et al. Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis. Blood 2011;117:3151-62.
35. Michels J, Johnson PW, Packham G. Mcl-1. Int J Biochem Cell Biol 2005;37:267-71.
36. Bose P, Grant S. Mcl-1 as a therapeutic target in acute myelogenous leukemia (AML). Leuk Res Rep 2013;2:12-4.
37. Huang CR, Yang-Yen HF. The fast-mobility isoform of mouse Mcl-1 is a mitochondrial matrix-localized protein with attenuated anti-apoptotic activity. FEBS Lett 2010;584:3323-30.
38. Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V, et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 2005;65:6282-93.
39. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006;107:257-64.
40. Yuan BZ, Chapman JA, Reynolds SH. Proteasome inhibitor MG132 induces apoptosis and inhibits invasion of human malignant pleural mesothelioma cells. Transl Oncol 2008;1:129-40.
41. Podar K, Gouill SL, Zhang J, Opferman JT, Zorn E, Tai YT, et al. A pivotal role for Mcl-1 in Bortezomib-induced apoptosis. Oncogene 2008;27: 721-31.
42. Brehme M, Hantschel O, Colinge J, Kaupe I, Planyavsky M, Kocher T, et al. Charting the molecular network of the drug target Bcr-Abl. Proc Natl Acad Sci U S A 2009;106:7414-9.
43. Sims JJ, Cohen RE. Linkage-specific avidity defines the lysine 63-linked polyubiquitin-binding preference of rap80. Mol Cell 2009;33: 775-83.
44. Heideker J, Wertz IE. DUBs, the regulation of cell identity and disease. Biochem J 2015;467:191.
45. Park Y, Jin HS, Liu YC. Regulation of T cell function by the ubiquitin-specific protease USP9X via modulating the Carma1-Bcl10-Malt1 complex. Proc Natl Acad Sci U S A 2013;110:9433-8.
46. Colland F. The therapeutic potential of deubiquitinating enzyme inhibitors. Biochem Soc Trans 2010;38:137-43.
47. Aleo E, Henderson CJ, Fontanini A, Solazzo B, Brancolini C. Identification of new compounds that trigger apoptosome-independent caspase activation and apoptosis. Cancer Res 2006;66:9235-44.
48. D'Arcy P, Brnjic S, Olofsson MH, Fryknas M, Lindsten K, De Cesare M, et al. Inhibition of proteasome deubiquitinating activityas anew cancer therapy. Nat Med 2011;17:1636-40.
49. Perry JW, Ahmed M, Chang KO, Donato NJ, Showalter HD, Wobus CE. Antiviral activity of a small molecule deubiquitinase inhibitor occurs via induction of the unfolded protein response. PLoS Pathog 2012;8: e1002783.
50. Zhang W, Sidhu SS. Development of inhibitors in the ubiquitination cascade. FEBS Lett 2014;588:356-67.